|Day Low/High||39.43 / 39.99|
|52 Wk Low/High||37.59 / 67.34|
Presentations Review Detailed Efficacy and Safety Data from Two Replicate Pivotal Phase 3 Studies; Report Prevalence of COPD Patients with Low Peak Inspiratory Flow Rate in Ongoing 12-Month Phase 3 Safety Trial
Donald Trump gives Wall Street a burst of relief on Monday after causing worry on markets for the previous two weeks.
Defense stocks lift Wall Street to begin the week after Donald Trump's first leg of a trip abroad results in billions of dollars' worth of deals.
Defense stocks lifted Wall Street to begin the week after Donald Trump's first leg of a trip abroad resulted in billions of dollars' worth of deals.
The firm upgraded Mylan to 'overweight' from 'equal weight.'
Carl Icahn exited his positions in Allergan and Nuance Communications during the first quarter of the year and acquired a stake in a Xerox spinoff after pressuring for a split.
Hikma shares plunged the most in nine months inLondon trading Thursday after the drugmaker said that approval of its generic Advair Diskus asthma treatment faces delays from the FDA.
Stocks trade mixed on Wednesday after Donald Trump's firing of FBI Director James Comey wraps the White House in another controversy.
Earlier this year the FDA sent Mylan a letter saying it would not approve its drug.
Stocks trade lower on Wednesday after Donald Trump's firing of FBI Director James Comey wraps the White House in another controversy.
Depomed unveiled steps the company is taking to shore itself up.
Hikma Pharmaceuticals fell sharply in London ahead of a crucial decision by the U.S. Food & Drug Administration on whether to approve its generic Advair asthma treatment.
Stock futures move lower on Wednesday after Donald Trump fires FBI Director James Comey in a move that shocked political pundits.
U.S. stock futures point lower Wednesday, suggesting Wall Street will follow European markets lower after Donald Trump fires James Comey as director of the FBI in a surprise move.
Mylan's moves away from the troubles of its EpiPen are yielding results, which should be reflected in first-quarter earnings.
We're rounding out the end of the earnings season and it's retail's turn to step up to the plate and show us what it's got.
The addition of Perrigo to the list of generics makers under investigation is more bad news for a sector already under pressure from low prices.
The investigation is in relation to drug pricing in the pharmaceutical industry.
Mylan was under scrutiny for drastically raising the price of its life-saving EpiPen allergic tratment.
AstraZeneca shares edged higher Tuesday after it passed another key milestone in its pivot toward an oncology focused portfolio.
Directors Douglas Leech, Joseph Maroon and Rodney Piatt to Retire from Board
Mylan's setback may not be enough to prevent generic Advair reaching the market in 2017
Fresenius announced a deal to buy U.S. generic drugmaker Akorn Inc for $4.75 billion, or $34 per share.